Group One Trading, L.P. Jounce Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$2.73 - $4.92 $6,371 - $11,483	2,334 New	2,334 $5,000
Q2 2022 Aug 11, 2022	SELL	$2.8 - $7.67 $6,300 - $17,257	-2,250 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $62,672 - $89,055	-10,428 Reduced 82.25%	2,250 $15,000
Q4 2021 Feb 11, 2022	BUY	$7.11 - $9.64 $59,724 - $80,976	8,400 Added 196.35%	12,678 $106,000
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $12,600 - $21,825	2,500 Added 140.61%	4,278 $32,000
Q2 2021 Aug 10, 2021	SELL	$6.58 - $10.66 $15,463 - $25,051	-2,350 Reduced 56.93%	1,778 $12,000
Q1 2021 May 12, 2021	BUY	$6.73 - $13.87 $27,781 - $57,255	4,128 New	4,128 $42,000
Q3 2020 Nov 12, 2020	SELL	$4.58 - $10.95 $17,220 - $41,172	-3,760 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$4.17 - $7.58 $15,016 - $27,295	-3,601 Reduced 48.92%	3,760 $26,000
Q1 2020 May 13, 2020	SELL	$2.91 - $8.7 $16,976 - $50,755	-5,834 Reduced 44.21%	7,361 $35,000
Q4 2019 Feb 10, 2020	BUY	$2.81 - $9.21 $30,780 - $100,886	10,954 Added 488.8%	13,195 $115,000
Q3 2019 Nov 12, 2019	SELL	$3.33 - $4.93 $7,878 - $11,664	-2,366 Reduced 51.36%	2,241 $7,000
Q2 2019 Aug 09, 2019	SELL	$4.3 - $6.73 $51,772 - $81,029	-12,040 Reduced 72.33%	4,607 $23,000
Q1 2019 May 13, 2019	BUY	$3.43 - $6.87 $56,485 - $113,135	16,468 Added 9200.0%	16,647 $103,000
Q4 2018 Feb 06, 2019	SELL	$2.69 - $6.71 $113,787 - $283,833	-42,300 Reduced 99.58%	179 $1,000
Q3 2018 Nov 08, 2018	BUY	$6.5 - $8.37 $276,113 - $355,549	42,479 New	42,479 $276,000
Q1 2018 May 11, 2018	SELL	$13.4 - $28.4 $7,611 - $16,131	-568 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$12.52 - $17.82 $7,111 - $10,121	568	568 $7,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account